Enanta Pharmaceuticals ENTA
$ 11.25
-2.13%
Quarterly report 2024-Q2
added 08-07-2024
Enanta Pharmaceuticals Balance Sheet 2011-2024 | ENTA
Annual Balance Sheet Enanta Pharmaceuticals
2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-58.9 M | -18.7 M | -51.9 M | - | -51 M | -63.6 M | -65.2 M | -16 M | -21.1 M | -30.5 M | -8.86 M | -10.5 M | -6.84 M |
Long Term Debt |
21.2 M | 22.4 M | 1.13 M | - | - | - | - | - | - | - | - | - | - |
Long Term Debt Current |
5.28 M | 2.89 M | 4.2 M | 4.26 M | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | 4.73 M | 4.52 M | 3.98 M | 3.45 M | 3.15 M | 2.02 M | 1.98 M | 2.5 M | 156 M |
Total Current Liabilities |
62.8 M | 29.8 M | 36.2 M | 24.2 M | 22.6 M | 16 M | 21 M | 7.89 M | 6.7 M | 4.75 M | 4.53 M | - | - |
Total Liabilities |
246 M | 54.1 M | 39.4 M | 30.6 M | 27.3 M | 20.5 M | 25 M | 11.3 M | 9.86 M | 6.76 M | 6.5 M | 8.23 M | 158 M |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | 10 K | 17 K | - |
Retained Earnings |
-207 M | -73.2 M | 48.6 M | 128 M | 164 M | 117 M | 45.4 M | 27.6 M | 5.98 M | -73 M | -107 M | -115 M | -132 M |
Total Assets |
462 M | 375 M | 439 M | 486 M | 490 M | 414 M | 327 M | 281 M | 246 M | 155 M | 117 M | 52.2 M | 26.1 M |
Cash and Cash Equivalents |
85.4 M | 44 M | 57.2 M | 87.1 M | 51.2 M | 63.9 M | 65.7 M | 16.6 M | 21.7 M | 30.7 M | 8.86 M | 10.5 M | 6.84 M |
Book Value |
217 M | 321 M | 399 M | 456 M | 462 M | 394 M | 302 M | 270 M | 236 M | 149 M | 110 M | 43.9 M | -132 M |
Total Shareholders Equity |
217 M | 321 M | 399 M | 456 M | 462 M | 394 M | 302 M | 270 M | 236 M | 149 M | 110 M | -115 M | -132 M |
All numbers in USD currency
Quarterly Balance Sheet Enanta Pharmaceuticals
2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
48.1 M | 43.4 M | 20.5 M | 21.2 M | 22.3 M | 23.1 M | 21.9 M | 22.4 M | 22.2 M | 15.1 M | 16 M | 1.13 M | 1.64 M | 1.13 M | 3.52 M | 3.84 M | 3.84 M | 3.84 M | 5.99 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
250 M | 247 M | 237 M | 246 M | 257 M | 57.1 M | 46.7 M | 54.1 M | 47.2 M | 48.2 M | 56.2 M | 39.4 M | 32.6 M | 39.4 M | 29 M | 30.6 M | 30.6 M | 30.6 M | 28.7 M | 27.3 M | 27.3 M | 27.3 M | 27.4 M | 20.5 M | 20.5 M | 20.5 M | 23.1 M | 25 M | 25 M | 25 M | 10.2 M | 11.3 M | 11.3 M | 11.3 M | 14.1 M | 9.86 M | 9.86 M | 9.86 M | 21.7 M | 6.76 M | 6.76 M | 6.76 M | 4.58 M | 6.5 M | 6.5 M | 6.5 M | - | 8.23 M | 8.23 M | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 51 K | 5 K | 10 K | 10 K | 10 K | - | 17 K | 17 K | - | - | - | - | - |
Retained Earnings |
-294 M | -272 M | -240 M | -207 M | -179 M | -140 M | -102 M | -73.2 M | -46.8 M | -15.1 M | 18.5 M | 48.6 M | 73.2 M | 48.6 M | 119 M | 128 M | 128 M | 128 M | 177 M | 164 M | 164 M | 164 M | 143 M | 117 M | 117 M | 117 M | 57.1 M | 45.4 M | 45.4 M | 45.4 M | 22.7 M | 27.6 M | 27.6 M | 27.6 M | 32.2 M | 5.98 M | 5.98 M | 5.98 M | -31 M | -73 M | -73 M | -73 M | -113 M | -107 M | -107 M | -107 M | - | -115 M | -115 M | - | - | - | - | - |
Total Assets |
399 M | 414 M | 428 M | 462 M | 495 M | 326 M | 348 M | 375 M | 385 M | 407 M | 441 M | 439 M | 450 M | 439 M | 481 M | 486 M | 486 M | 486 M | 511 M | 490 M | 490 M | 490 M | 454 M | 414 M | 414 M | 414 M | 341 M | 327 M | 327 M | 327 M | 278 M | 281 M | 281 M | 281 M | 278 M | 246 M | 246 M | 246 M | 215 M | 155 M | 155 M | 155 M | 110 M | 117 M | 117 M | 117 M | - | 52.2 M | 52.2 M | - | - | - | - | - |
Cash and Cash Equivalents |
35.8 M | 63.5 M | 39.9 M | 85.4 M | 95.2 M | 73.2 M | 42.2 M | 44 M | 28.4 M | 41 M | 99.1 M | 57.2 M | 4.6 M | 57.2 M | 55.1 M | 87.1 M | 87.1 M | 87.1 M | 27.6 M | 51.2 M | 51.2 M | 51.2 M | 74.4 M | 63.9 M | 63.9 M | 63.9 M | 68.1 M | 65.7 M | 65.7 M | 65.7 M | 20.6 M | 16.6 M | 16.6 M | 20.6 M | 46.2 M | 21.7 M | 21.7 M | 46.2 M | 34.1 M | 30.7 M | 30.7 M | 34.1 M | 4.43 M | 8.86 M | 8.86 M | 4.43 M | 20.7 M | 10.5 M | 10.5 M | 20.7 M | - | 6.84 M | - | - |
Book Value |
149 M | 166 M | 192 M | 217 M | 238 M | 269 M | 301 M | 321 M | 338 M | 359 M | 384 M | 399 M | 418 M | 399 M | 452 M | 456 M | 456 M | 456 M | 482 M | 462 M | 462 M | 462 M | 427 M | 394 M | 394 M | 394 M | 318 M | 302 M | 302 M | 302 M | 268 M | 270 M | 270 M | 270 M | 264 M | 236 M | 236 M | 236 M | 194 M | 149 M | 149 M | 149 M | 106 M | 110 M | 110 M | 110 M | - | 43.9 M | 43.9 M | - | - | - | - | - |
Total Shareholders Equity |
149 M | 166 M | 192 M | 217 M | 238 M | 269 M | 301 M | 321 M | 338 M | 359 M | 384 M | 399 M | 418 M | 436 M | 452 M | 456 M | 452 M | 452 M | 482 M | 482 M | 482 M | 482 M | 427 M | 427 M | 427 M | 427 M | 318 M | 302 M | 302 M | 318 M | 268 M | 270 M | 270 M | 270 M | 264 M | 236 M | 236 M | 236 M | 194 M | 149 M | 149 M | 149 M | 106 M | 110 M | 110 M | 110 M | - | -115 M | -115 M | - | - | -132 M | - | - |
All numbers in USD currency